Famotidine vs Omeprazole: Key Differences
Omeprazole (a proton pump inhibitor) provides superior acid suppression and more effective ulcer healing compared to famotidine (an H2-receptor antagonist), but famotidine has fewer drug interactions and no effect on CYP450 metabolism.
Mechanism of Action
Omeprazole irreversibly blocks the H+/K+ ATPase enzyme (proton pump) at the parietal cell secretory surface, representing the final step of acid production 1. This inhibition lasts 24-72 hours despite a plasma half-life under one hour, due to prolonged enzyme binding 1.
Famotidine competitively blocks histamine-2 receptors on parietal cells 2. Its acid-inhibiting effects last approximately 6 hours, requiring 2-3 times daily dosing for sustained effect 3.
Acid Suppression Efficacy
- Omeprazole achieves 78-94% reduction in basal acid output and 79-88% reduction in peak acid output with standard dosing 1
- Famotidine provides significantly less acid suppression than PPIs 4
- Omeprazole demonstrates "potentiation" with repeated dosing (increasing effectiveness over days 1-15), while famotidine shows "tolerance" phenomenon (decreasing effectiveness) 5
- Standard-dose H2RAs like famotidine do not prevent most NSAID-related gastric ulcers, whereas PPIs are superior 4, 6
Clinical Efficacy for Ulcer Healing
Omeprazole demonstrates superior ulcer healing rates:
- Duodenal ulcer healing at 2 weeks: 62-77% (omeprazole) vs 33-40% (famotidine) 7, 8
- Duodenal ulcer healing at 4 weeks: 92-93% (omeprazole) vs 80% (famotidine) 7, 8
- For iatrogenic ulcers post-endoscopic mucosal resection, omeprazole showed superiority, particularly for large ulcers 9
- Omeprazole provides more rapid pain relief and lower antacid consumption 7
Drug Metabolism and Interactions
Critical difference for transplant patients and those on antiplatelet therapy:
Omeprazole:
- Metabolized by CYP2C19, CYP3A4, and CYP3A5 10, 11
- Inhibits CYP2C19, CYP3A4, and CYP3A5 enzymes 10, 12
- Increases tacrolimus blood concentrations significantly (AUC increased by 16% after single dose) 13
- May reduce clopidogrel activation through CYP2C19 competitive inhibition 10
- Decreases glecaprevir concentrations by 64% when co-administered 11
Famotidine:
- 50-80% hepatic metabolism, but does NOT bind to cytochrome P-450 system 10
- No clinically significant drug interactions with tacrolimus, clopidogrel, or other CYP450-dependent medications 10, 13
- Safe alternative when drug interactions are a concern 14
Dosing and Duration of Effect
Omeprazole:
- Standard dose: 20 mg once daily 1
- Onset within 1 hour, maximum effect at 2 hours 1
- Effect plateaus after 4 days of repeated dosing 1
- Acid suppression lasts 24-72 hours 1
Famotidine:
- Standard dose: 20 mg twice daily 15, 2
- Peak plasma concentration at 2.5 hours 3
- Effect duration approximately 6 hours 3
- Tachyphylaxis develops within 6 weeks, limiting long-term effectiveness 3
Specific Clinical Scenarios
For stress ulcer prophylaxis in ICU: Both agents are acceptable, though PPIs show reduced clinically important upper GI bleeding (RR 0.53) compared to H2RAs, but possibly increased mortality (RR 1.05) 15.
For patients on antiplatelet therapy (aspirin/clopidogrel): Famotidine is preferred to avoid potential CYP2C19-mediated reduction in clopidogrel efficacy 10, 14. The FAMOUS trial demonstrated famotidine 20 mg twice daily reduced gastric ulcers (3.4% vs 15% placebo) without interfering with antiplatelet effects 14.
For kidney transplant patients on tacrolimus: Famotidine is strongly preferred as omeprazole significantly increases tacrolimus exposure, requiring dose adjustments and increasing toxicity risk 12, 13.
For gastroesophageal reflux disease: Omeprazole 20 mg once daily is superior to famotidine for symptom control and maintenance of remission 16, 17.
For prevention of NSAID-related ulcers: PPIs are superior to standard-dose H2RAs; double-dose H2RAs show some efficacy but primarily in H. pylori-positive patients 6.
Safety Considerations
Omeprazole:
- Increases serum gastrin levels (1.3-3.6 fold) 1
- May cause false-positive chromogranin A results 1
- Associated with potential increased infection risk due to profound acid suppression 15
Famotidine:
- Excellent safety profile with minimal adverse effects 14
- No significant drug-drug interactions 10
- Cimetidine (another H2RA) specifically linked to liver disease and gynecomastia, though this may not apply to famotidine 3
Cost and Availability
Both medications are now available generically with omeprazole's patent expired, making cost differences minimal 6.